| . | Odds ratio . | 95% confidence interval . | P-value . |
|---|---|---|---|
| TAVR cohort | |||
| Aortic valve maximum gradient (per 1 mmHg increase) | 1.01 | 1.00–1.02 | 0.03 |
| Aortic valve stenosis and regurgitation | 1.92 | 1.20–3.08 | 0.007 |
| Systolic pulmonary artery pressure >55 mmHg | 5.95 | 1.69–20.95 | 0.005 |
| Predilatation of the native valve | 3.43 | 1.87–6.29 | <0.001 |
| Self-expanding valve prosthesis | 2.47 | 1.10–5.57 | 0.03 |
| Newer generation valve prostheses | 0.23 | 0.14–0.40 | <0.001 |
| SAVR cohort | |||
| Male | 3.21 | 1.29–7.94 | 0.01 |
| Porcelain aorta | 12.98 | 1.61–104.58 | 0.02 |
| Prior cardiac surgery | 4.22 | 1.24–14.37 | 0.02 |
| . | Odds ratio . | 95% confidence interval . | P-value . |
|---|---|---|---|
| TAVR cohort | |||
| Aortic valve maximum gradient (per 1 mmHg increase) | 1.01 | 1.00–1.02 | 0.03 |
| Aortic valve stenosis and regurgitation | 1.92 | 1.20–3.08 | 0.007 |
| Systolic pulmonary artery pressure >55 mmHg | 5.95 | 1.69–20.95 | 0.005 |
| Predilatation of the native valve | 3.43 | 1.87–6.29 | <0.001 |
| Self-expanding valve prosthesis | 2.47 | 1.10–5.57 | 0.03 |
| Newer generation valve prostheses | 0.23 | 0.14–0.40 | <0.001 |
| SAVR cohort | |||
| Male | 3.21 | 1.29–7.94 | 0.01 |
| Porcelain aorta | 12.98 | 1.61–104.58 | 0.02 |
| Prior cardiac surgery | 4.22 | 1.24–14.37 | 0.02 |
SAVR: surgical aortic valve replacement; TAVR: transcatheter aortic valve replacement.
| . | Odds ratio . | 95% confidence interval . | P-value . |
|---|---|---|---|
| TAVR cohort | |||
| Aortic valve maximum gradient (per 1 mmHg increase) | 1.01 | 1.00–1.02 | 0.03 |
| Aortic valve stenosis and regurgitation | 1.92 | 1.20–3.08 | 0.007 |
| Systolic pulmonary artery pressure >55 mmHg | 5.95 | 1.69–20.95 | 0.005 |
| Predilatation of the native valve | 3.43 | 1.87–6.29 | <0.001 |
| Self-expanding valve prosthesis | 2.47 | 1.10–5.57 | 0.03 |
| Newer generation valve prostheses | 0.23 | 0.14–0.40 | <0.001 |
| SAVR cohort | |||
| Male | 3.21 | 1.29–7.94 | 0.01 |
| Porcelain aorta | 12.98 | 1.61–104.58 | 0.02 |
| Prior cardiac surgery | 4.22 | 1.24–14.37 | 0.02 |
| . | Odds ratio . | 95% confidence interval . | P-value . |
|---|---|---|---|
| TAVR cohort | |||
| Aortic valve maximum gradient (per 1 mmHg increase) | 1.01 | 1.00–1.02 | 0.03 |
| Aortic valve stenosis and regurgitation | 1.92 | 1.20–3.08 | 0.007 |
| Systolic pulmonary artery pressure >55 mmHg | 5.95 | 1.69–20.95 | 0.005 |
| Predilatation of the native valve | 3.43 | 1.87–6.29 | <0.001 |
| Self-expanding valve prosthesis | 2.47 | 1.10–5.57 | 0.03 |
| Newer generation valve prostheses | 0.23 | 0.14–0.40 | <0.001 |
| SAVR cohort | |||
| Male | 3.21 | 1.29–7.94 | 0.01 |
| Porcelain aorta | 12.98 | 1.61–104.58 | 0.02 |
| Prior cardiac surgery | 4.22 | 1.24–14.37 | 0.02 |
SAVR: surgical aortic valve replacement; TAVR: transcatheter aortic valve replacement.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
